Article PDF first page preview

First page of Keratitis, Ichthyosis and Deafness (KID) Syndrome and Beta-Thalassemia with Endocarditis and Myelitis: A Rare Case Report

Keratitis-Ichthyosis-Deafness syndrome (KID, MIM#148210) is a rare autosomal dominant genodermatosis caused by monoallelic deleterious variants in the GJB2 gene (MIM*121011). The syndrome is characterized by congenital neurosensory deafness, keratitis, and palmoplantar keratoderma. We report on a 32-year-old Caucasian male with KID syndrome who presented to the emergency department with high fever, severe headache, and chest pain exacerbated by coughing and deep breathing. His symptoms rapidly progressed to sepsis, and diagnostic evaluations confirmed endocarditis, complicated by parainfectious myelitis. Despite the severity of his condition, the patient achieved significant recovery, with minimal residual neurological deficits affecting the left leg. We attribute the sepsis to systemic dissemination of Staphylococcus aureus, probably facilitated by impaired skin barrier due to KID syndrome. This case highlights the importance of comprehensive interprofessional management in managing rare genodermatoses and their complications.

The Author(s). Published by S. Karger AG, Basel
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License .
Attribution-NonCommercial